Identifying trial-relevant concepts of interest in HSP: insights from an international patient-voice study in >600 individuals

Through an international study of over 600 patients, this research establishes a regulatory-compliant framework of patient-prioritized health domains—specifically mobility, lower body function, autonomic dysregulation, pain, and psychosocial aspects—to guide the development of outcome measures for future hereditary spastic paraplegia clinical trials.

The Gist

Imagine Hereditary Spastic Paraplegia (HSP) as a complex, foggy landscape that patients have to navigate every day. For a long time, doctors and researchers have been trying to build "therapeutic vehicles" (new drugs and treatments) to help people cross this terrain, but they didn't have a good map of what the travelers actually care about most. They were guessing which obstacles were the hardest to climb.

This paper is like a massive, international town hall meeting where over 600 people living with HSP finally got to draw their own map.

Here is the breakdown of what they did and what they found, using some everyday comparisons:

The Mission: Building the Right Compass

When scientists test new medicines, they need a "compass" to see if the treatment is working. In the past, they might have used a compass that only pointed toward things doctors thought were important (like muscle stiffness). But this study asked: "What actually matters to the people walking the path?"

They wanted to create a regulatory-compliant framework—which is just a fancy way of saying, "Let's build a rulebook that the FDA and other health agencies will accept, based entirely on what patients say hurts the most."

The Process: Two Big Surveys

The researchers didn't just ask a few people; they held two massive online surveys (like sending out postcards to the whole world) to gather data from 616 and then 504 patients. They spoke many languages and included people with different types of HSP, ensuring no one was left out of the conversation.

They used a "staged approach," which is like sifting sand through a series of sieves:

1. The Big Sieve: What problems do everyone have? (Prevalence)
2. The Medium Sieve: Which of those problems get worse as time goes on? (Sensitivity to progression)
3. The Fine Sieve: Which of those problems make patients say, "This is the thing I want fixed most"? (Relevance)
4. The Final Filter: Do the things that hurt the most also feel the most severe? (Correlation)

The Results: The "Big Five" Obstacles

After all that sifting, the patients pointed to five main "mountains" they need help climbing:

1. Mobility: The ability to move around.
2. Lower Body Function: How the legs and hips work.
3. Autonomic Dysregulation: This is the body's "autopilot" system (like bladder and bowel control) going haywire.
4. Pain: The physical ache.
5. Psychosocial Aspects: The mental and emotional weight of the disease.

The Headline Finding:
Across the board, walking and leg function were the top priorities. It's like saying, "If you can't walk, you can't do anything else."

However, the map gets more detailed depending on where you are on the journey:

• For those in the early stages (Mild HSP): The biggest worries are small but frustrating things, like walking a shorter distance than before, walking slower, or feeling a sudden, urgent need to use the bathroom. It's like a car that starts sputtering before it completely breaks down; the driver notices the change in speed and fuel efficiency first.
• For non-motor issues (things not related to walking): The biggest pain points were losing the ability to work, bladder accidents, and exhaustion (fatigue).

Why This Matters

Think of this study as calibrating the GPS for future medical trials.

Before this, researchers might have been driving in the wrong direction, testing drugs on things patients didn't care about. Now, they have a precise, patient-drawn map. When a new drug is tested in the future, scientists will use these specific "landmarks" (like walking speed or bladder urgency) to measure success.

In short: This paper ensures that the next generation of HSP treatments will be judged by whether they help patients walk further, work better, and feel less tired, rather than just by numbers on a lab chart. It puts the patient's voice in the driver's seat.

Technical Summary

Technical Summary: Identifying Trial-Relevant Concepts of Interest in HSP

Problem Statement
As therapeutic interventions for Hereditary Spastic Paraplegias (HSP) begin to emerge, a critical gap exists in clinical trial design: the lack of validated outcome measures that accurately reflect the health aspects most important to patients. While HSP is a heterogeneous group of disorders with a wide clinical and genetic spectrum, patient priorities have historically been poorly defined. Consequently, there is a risk that clinical trials may measure endpoints that do not correlate with the patient experience, potentially leading to the failure of promising therapies to demonstrate efficacy in regulatory settings. The core problem is the need to establish a regulatory-compliant framework of patient-prioritized health domains to serve as the basis for future treatment response evaluation.

Methodology
The study employed a rigorous, staged, and patient-centric approach to develop a framework for identifying "concepts of interest" (COIs) for clinical trials.

• Data Collection: Two sequential, multinational, multilingual online surveys were conducted. The first survey included 616 participants, and the second included 504 participants, collectively covering the broad clinical and genetic spectrum of HSP.
• Stakeholder Involvement: Patient representatives were integrated centrally into the study design and the prioritization process, ensuring the research remained grounded in the patient voice.
• Analytical Framework: The researchers utilized a multi-criteria filtering process to identify high-value health impacts. A concept was prioritized if it met four specific criteria:
  1. Prevalence: The impact must be common across the population.
  2. Sensitivity: The impact must be sensitive to disease progression.
  3. Relevance: The impact must be highly relevant to the patient's daily life.
  4. Correlation: There must be a strong correlation between the severity of the impact and its relevance to the patient.
• Stratification: Analysis was conducted across different disease stages (mild to severe) to ensure the findings were applicable across the HSP spectrum.

Key Contributions

• Regulatory-Compliant Framework: The study provides a structured, regulatory-aligned methodology for defining patient-reported outcomes (PROs) specifically for rare neurodegenerative diseases.
• Comprehensive Profiling: It offers the most extensive patient-reported and disease-stage-specific profiling of HSP health impacts to date.
• Patient-Centric Design: By embedding patient representatives in the design phase, the study sets a precedent for "patient-focused drug development" in rare disease contexts.

Key Results
The analysis yielded five core health domains that are highly prevalent and relevant across the HSP population:

1. Mobility
2. Lower Body Function
3. Autonomic Dysregulation
4. Pain
5. Psychosocial Aspects

Specific Findings by Domain and Stage:

• Overall Ranking: Ambulation and lower body function were ranked as the highest priority across all disease stages.
• Non-Motor Impacts: Among non-motor symptoms, the reduced ability to work, bladder incontinence, and fatigue were identified as the most relevant to patients.
• Mild Disease Stages: In early-stage disease, the most frequent and relevant impacts were specifically identified as reduced walking distance, reduced walking speed, and the urgency to empty the bladder.
• Severity-Relevance Correlation: The study confirmed a strong correlation between the severity of symptoms and their relevance to patients, validating the use of severity as a proxy for patient priority in trial design.

Significance
This work serves as a foundational step for the future of HSP clinical trials. By defining a specific set of patient-prioritized concepts, the study enables the development of targeted, patient-focused outcome tools. These tools are essential for:

• Trial Sensitivity: Ensuring that clinical trials can detect subtle but meaningful treatment effects that matter to patients.
• Regulatory Approval: Providing the evidence base required by regulatory agencies (such as the FDA and EMA) to accept patient-reported outcomes as primary or secondary endpoints.
• Therapeutic Development: Guiding pharmaceutical developers to focus on endpoints that align with the actual burden of the disease, thereby increasing the likelihood of successful drug development and approval for HSP therapies.